Paul M Sondel

List of Publications by Year
in descending order

88 papers	5,437 citations	126907 33 h-index	88630 70 g-index
90 all docs	90 docs citations	90 times ranked	5781 citing authors

#	Article	IF	Citations
1	Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. New England Journal of Medicine, 2010, 363, 1324-1334.	27.0	1,460
2	NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Frontiers in Immunology, 2015, 6, 368.	4.8	411
3	Irinotecanâ€“temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 946-957.	10.7	205
4	A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children's Oncology Group. Clinical Cancer Research, 2006, 12, 1750-1759.	7.0	176
5	A Phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer, 1997, 80, 317-333.	4.1	159
6	Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients. Journal of Clinical Oncology, 2004, 22, 4463-4473.	1.6	141
7	Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 1445-1452.	1.6	134
8	In SituTumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Research, 2016, 76, 3929-3941.	0.9	120
9	A multigene family on human chromosome 12 encodes natural killer-cell lectins. Immunogenetics, 1993, 37, 455-60.	2.4	118
10	A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma. Clinical Cancer Research, 2017, 23, 6441-6449.	7.0	116
11	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. Lancet Oncology, The, 2018, 19, e240-e251.	10.7	108
12	Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model. OncoImmunology, 2019, 8, 1553477.	4.6	103
13	Immunocytokines for cancer treatment: past, present and future. Current Opinion in Immunology, 2016, 40, 96-102.	5.5	101
14	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 2160-2169.	1.6	98
15	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research, 2021, 27, 2179-2189.	7.0	95
16	Lymphokines and cytokines as cancer treatment.Immunotherapy realized. Cancer, 1990, 65, 800-814.	4.1	93
17	Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Science Translational Medicine, 2021, 13, .	12.4	92
18	Enhanced Activity of Hu14.18-IL2 Immunocytokine against Murine NXS2 Neuroblastoma when Combined with Interleukin 2 Therapy. Clinical Cancer Research, 2004, 10, 4839-4847.	7.0	91

#	Article	IF	Citations
19	Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism. Cancer Gene Therapy, 2000, 7, 826-838.	4.6	67
20	A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Childrenâ€™s Oncology Group Study ANBL0931. Frontiers in Immunology, 2018, 9, 1355.	4.8	66
21	Intratumoral hu14.18â€“IL-2 (IC) Induces Local and Systemic Antitumor Effects That Involve Both Activated T and NK Cells As Well As Enhanced IC Retention. Journal of Immunology, 2012, 189, 2656-2664.	0.8	64
22	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
23	Tumor-Specific Inhibition ofIn SituVaccination by Distant Untreated Tumor Sites. Cancer Immunology Research, 2018, 6, 825-834.	3.4	61
24	A Phase II Trial of Hu14.18K322A in Combination with Induction Chemotherapy in Children with Newly Diagnosed High-Risk Neuroblastoma. Clinical Cancer Research, 2019, 25, 6320-6328.	7.0	61
25	Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy. Immunotherapy, 2016, 8, 1097-1117.	2.0	58
26	Anti-GD2 strategy in the treatment of neuroblastoma. Drugs of the Future, 2010, 35, 665.	0.1	57
27	Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunology, Immunotherapy, 2008, 57, 1891-1902.	4.2	47
28	Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A. Journal of Clinical Oncology, 2022, 40, 335-344.	1.6	46
29	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clinical Cancer Research, 2018, 24, 189-196.	7.0	45
30	Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition. , 2019, 7, 344.		45
31	Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. Cancer Immunology, Immunotherapy, 2013, 62, 1303-1313.	4.2	44
32	Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunology, Immunotherapy, 1999, 48, 219-229.	4.2	43
33	Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults With Melanoma and Children With Neuroblastoma. Clinical Cancer Research, 2009, 15, 5923-5930.	7.0	41
34	90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkinâ€™s Lymphoma. Communications Biology, 2019, 2, 79.	4.4	39
35	Central venous device-related infection and thrombosis in patients treated with moderate dose continuous-infusion interleukin-2. Cancer, 2001, 91, 806-814.	4.1	36
36	Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. Antibodies, 2012, 1, 149-171.	2.5	36

#	Article	IF	Citations
37	the influence of autologous lymphokine-activated killer cell infusions on the toxicity and antitumor effect of repetitive cycles of interleukin-2. Cancer, 1990, 66, 2457-2464.	4.1	31
38	Immunotherapy of Neuroblastoma: Facts and Hopes. Clinical Cancer Research, 2022, 28, 3196-3206.	7.0	29
39	Systemic Interleukin-2 Modulates the Anti-Idiotypic Response to Chimeric Anti-GD2 Antibody in Patients with Melanoma. Journal of Immunotherapy, 1996, 19, 278-295.	2.4	26
40	Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice. , 2021, 9, e002715.		26
41	A Phase Ib/II trial of granulocyte-macrophage?colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases. Cancer, 2000, 88, 1892-1901.	4.1	25
42	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. Journal of Translational Medicine, 2017, 15, 223.	4.4	25
43	Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunology, Immunotherapy, 2018, 67, 1647-1658.	4.2	25
44	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma. Cancer Immunology Research, 2015, 3, 881-890.	3.4	24
45	MUC16 suppresses human and murine innate immune responses. Gynecologic Oncology, 2019, 152, 618-628.	1.4	24
46	Interleukin-12 as an in situ cancer vaccine component: a review. Cancer Immunology, Immunotherapy, 2022, 71, 2057-2065.	4.2	22
47	Analysis of T cell receptor Î² and Î³ genes from peripheral blood, regional lymph node and tumor-infiltrating lymphocyte clones from melanoma patients. Cancer Immunology, Immunotherapy, 1991, 32, 325-330.	4.2	20
48	Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion. Cancer Immunology, Immunotherapy, 2016, 65, 1047-1059.	4.2	20
49	Genetic Control of Mixed Leukocyte Culture Reactivity. Immunological Reviews, 1972, 12, 30-56.	6.0	19
50	Potentiation of differential hyperthermic sensitivity of AKR leukemia and normal bone marrow cells by lidocaine or thiopental. Cancer, 1984, 54, 2831-2835.	4.1	19
51	Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab. , 2019, 7, 70.		19
52	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 675.	4.8	18
53	Pleasant memories: remembering immune protection while forgetting about graft-versus-host disease. Journal of Clinical Investigation, 2003, 112, 25-27.	8.2	17
54	Intravital Metabolic Autofluorescence Imaging Captures Macrophage Heterogeneity Across Normal and Cancerous Tissue. Frontiers in Bioengineering and Biotechnology, 2021, 9, 644648.	4.1	16

#	Article	IF	Citations
55	Prolonged Interleukin-2 (IL-2) Treatment Can Augment Immune Activation Without Enhancing Antitumor Activity in Renal Cell Carcinom. Cancer Investigation, 1991, 9, 35-48.	1.3	15
56	Synergy of anti-CD40, CpG and MPL in activation of mouse macrophages. Molecular Immunology, 2015, 66, 208-215.	2.2	15
57	Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model. Journal of Immunology, 2017, 198, 1575-1584.	0.8	15
58	Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model. , 2020, 8, e001262.		14
59	Analysis of ex vivo expanded and activated clinical-grade human NK cells after cryopreservation. Cytotherapy, 2020, 22, 450-457.	0.7	14
60	Preclinical and clinical development of immunocytokines. Current Opinion in Investigational Drugs, 2003, 4, 696-700.	2.3	14
61	Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody-Interleukin-2 Immunocytokine. , 2003, 85, 123-132.		12
62	Donor selection for ex vivo-expanded natural killer cells as adoptive cancer immunotherapy. Future Oncology, 2017, 13, 1043-1047.	2.4	12
63	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 2159-2168.	7.0	12
64	In situ Vaccine Plus Checkpoint Blockade Induces Memory Humoral Response. Frontiers in Immunology, 2020, 11, 1610.	4.8	12
65	Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2. Clinical Cancer Research, 2020, 26, 3296-3306.	7.0	12
66	Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. PLoS ONE, 2021, 16, e0255798.	2.5	12
67	Stress Keratin 17 Expression in Head and Neck Cancer Contributes to Immune Evasion and Resistance to Immune-Checkpoint Blockade. Clinical Cancer Research, 2022, 28, 2953-2968.	7.0	12
68	Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein. Biotherapy (Dordrecht, Netherlands), 1990, 2, 193-198.	0.7	11
69	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 4107-4118.	1.6	11
70	Radiation Augments the Local Anti-Tumor Effect of In Situ Vaccine With CpG-Oligodeoxynucleotides and Anti-OX40 in Immunologically Cold Tumor Models. Frontiers in Immunology, 2021, 12, 763888.	4.8	9
71	Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells. Methods in Molecular Biology, 2016, 1441, 43-56.	0.9	8
72	Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines. OncoImmunology, 2019, 8, e1238538.	4.6	8

#	Article	IF	Citations
73	Depth of tumor implantation affects response to in situ vaccination in a syngeneic murine melanoma model. , 2021, 9, e002107.		8
74	A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Childrenâ€™s Oncology Group study.. Journal of Clinical Oncology, 2015, 33, 10017-10017.	1.6	7
75	Short-course neoadjuvant in situ vaccination for murine melanoma. , 2022, 10, e003586.		7
76	In Vivo Effects of Multiple Cycles of Recombinant Interleukin-2 (IL2) on Peripheral Granulocyte-macrophage Hematopoietic Progenitors Circulating in the Blood of Cancer Patients. Tumori, 1991, 77, 420-422.	1.1	6
77	Killer immunoglobulin-like receptor (KIR) and KIRâ€“ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunology, Immunotherapy, 2016, 65, 1523-1532.	4.2	5
78	Strategies for improving antitumor activity utilizing IL-2: Preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2. Biotherapy (Dordrecht, Netherlands), 1992, 4, 189-198.	0.7	4
79	A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors. MAbs, 2020, 12, 1773751.	5.2	4
80	Combining Immunocytokine and Ex Vivo Activated NK Cells as a Platform for Enhancing Graft-Versus-Tumor Effects Against GD2+ Murine Neuroblastoma. Frontiers in Immunology, 2021, 12, 668307.	4.8	4
81	Mechanism of effective combination radio-immunotherapy against 9464D-GD2, an immunologically cold murine neuroblastoma. , 2022, 10, e004834.		4
82	Biologic and immunologic approaches to comprehensive therapy for pediatric malignant conditions. Laboratoryâ€“clinical interaction. Cancer, 1993, 71, 3429-3434.	4.1	3
83	Optimizing Flow Cytometric Analysis of Immune Cells in Samples Requiring Cryopreservation from Tumor-Bearing Mice. Journal of Immunology, 2021, 207, ji2000656.	0.8	3
84	Pre-existing antitherapeutic antibodies against the Fc region of the hu14.18K322A mAb are associated with outcome in patients with relapsed neuroblastoma. , 2020, 8, e000590.		1
85	Reduction in oral mucositis severity using a topical vasoconstrictor: A case report of three bone marrow transplant patients. Integrative Cancer Science and Therapeutics, 2018, 5, .	0.1	1
86	BLT-esterase activity followingin vitro andin vivo activation of human lymphocytes with interleukin-2. Biotherapy (Dordrecht, Netherlands), 1991, 3, 253-260.	0.7	0
87	Mac Cheever (1944â€“2021): a tribute to a life of achievement and service. , 2022, 10, e004433.		0
88	Expression of neuroblastomaâ€related genes in bone marrow at end of highâ€risk neuroblastoma therapy. Pediatric Blood and Cancer, 2022, , e29719.	1.5	0